Ascidian and Exegenesis partner to combine RNA exon editing with AI-engineered AAV capsids, advancing targeted delivery for genetic medicines.
Written By: Creola Gonsalves, MS Biotech
Reviewed By: Pharmacally Editorial Team
Ascidian Therapeutics and Exegenesis Bio have entered a strategic agreement to combine RNA exon editing with AI-enabled adeno-associated virus (AAV) capsid engineering, advancing targeted delivery strategies for genetic medicines. The collaboration will evaluate program-specific combinations of RNA exon editors and next-generation AAV capsids, with ongoing scientific work focused on generating in vivo data and supporting progression toward clinical development.
Addressing the Delivery Challenge in Genetic Medicines
Efficient and tolerable delivery remains a major obstacle in genetic medicine development. Although therapeutic payloads may demonstrate biological potential, their clinical utility depends on reaching the appropriate cells and tissues at sufficient levels without exposing non-target tissues to unnecessary treatment.
AAV vectors offer an established approach to delivering genetic material into target cells. However, conventional capsids often face limitations in tissue specificity and delivery efficiency. Engineered AAV capsids can potentially improve tissue targeting, reduce off-target exposure outside the intended tissues, and support therapeutic delivery at lower, more tolerable doses.
For Boston-based Ascidian Therapeutics, a clinical-stage biotechnology company pioneering RNA exon editing (including its lead clinical candidate ACDN-01 for Stargardt disease), solving this delivery challenge is essential because its platform targets diseases caused by genetic abnormalities across multiple tissue types. The company conducted a global search for AAV capsid engineering partners before selecting Exegenesis Bio, a clinical-stage gene therapy developer with operations in the United States and China, to evaluate delivery technologies compatible with its therapeutic platform.
Combining RNA Exon Editing With AI-Enabled Capsid Discovery
Ascidian’s platform uses post-transcriptional RNA editing to replace large mutated exons and generate full-length, functional proteins. Unlike conventional DNA editing approaches, which alter the underlying genetic sequence, RNA exon editing acts at the RNA level, providing an alternative strategy for correcting the consequences of genetic mutations without introducing permanent changes to the genome.
The company has partnered and wholly owned programs spanning retinal, renal, neurological, neuromuscular, and other genetically defined diseases. Because the RNA exon editor is delivered via a durable AAV vector that persists in target cells, the approach could potentially enable long-term protein restoration from a single dose—while overcoming the strict ~4.7 kilobase cargo-size limits that restrict conventional gene replacement and larger DNA-editing systems. The clinical applicability and durability of this strategy across broader tissue types will require further validation.
Exegenesis will contribute its proprietary AAVarta® platform, which integrates artificial intelligence algorithms with high-throughput experimental screening to discover and optimize AAV capsids with distinct delivery profiles. The platform will support the identification of capsids with tissue-specific delivery characteristics suited to individual RNA exon editing programs, helping address differences in tissue accessibility and delivery requirements across disease indications.
Non-Exclusive Agreement Preserves Development Flexibility
Under the agreement, the companies will evaluate Exegenesis’ existing AAV capsids and capsid discovery capabilities against the delivery requirements of individual RNA exon editing programs. Scientific assessments and predefined target capsid profiles will guide the selection of compatible RNA exon editor-capsid combinations for further in vivo evaluation and potential clinical development, with Ascidian retaining responsibility for the subsequent execution of the resulting combinations.
The non-exclusive structure allows Ascidian to continue working with other capsid engineering providers when necessary. It also preserves the company’s flexibility to select clinical and commercial manufacturing partners according to individual program requirements.
Exegenesis retains the right to independently or collaboratively develop the relevant capsids outside Ascidian’s RNA exon editing programs. The companies have not disclosed specific target indications, individual program details, or financial terms for the agreement.
Delivery Optimization Becomes a Key Development Priority
Daniel Rosan, President, Chief Financial and Business Officer of Ascidian Therapeutics, highlighted the importance of matching delivery strategies to individual patient populations and therapeutic programs. Exegenesis CEO Zhenhua Wu, Ph.D., emphasized the potential of AI-assisted capsid engineering to expand delivery options across different tissue types.
The agreement reflects a broader development reality for genetic medicines: therapeutic editing capabilities alone are insufficient without reliable, targeted delivery to the intended cells. For Ascidian, access to programmable capsid discovery could expand the potential application of RNA exon editing across multiple disease areas. However, the partnership’s value will ultimately depend on whether the selected capsids demonstrate sufficient tissue targeting, delivery efficiency, and tolerability in preclinical studies.
The next major milestone for the collaboration will be the generation of in vivo proof-of-concept data supporting specific RNA exon editor-capsid combinations. Neither company has disclosed a clinical development timeline for the partnered programs.
Reference
Ascidian and Exegenesis Bio Enter Strategic Agreement to Accelerate Development of RNA Exon Editors with Next-Generation AAV Capsids, Ascidian Therapeutics, 12 November 2026
About the Writer
Creola Gonsalves (Linkedin) is an M.S. Biotechnology postgraduate with a strong interest in clinical research, evidence interpretation, and healthcare writing, with a focus on translating life-science knowledge into meaningful real-world insights.
She is trained in Good Clinical Practice (GCP), clinical research principles, and critical interpretation of randomized clinical trials, with certifications from NIH and Stanford University.
Her research background in biotechnological applications and microbial research strengthens her ability to understand scientific evidence and develop clear, accurate, and research-driven healthcare content.